Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear and AuraLux, and facilitate the company’s global market expansion.

Accelmed Partners spearheaded the funding round, which also received support from the current investor, 3E Bioventures Capital.

Acclaro Medical co-founder and CEO Helen Fang said: "This funding empowers us to continue our strong growth and realise our vision of improving the quality of life for people of all skin colours and all ages worldwide."

UltraClear comprises a 2,910nm cold ablative fibre laser that leverages 3DIntelliPulse technology and offers enhanced safety across all types of skin.

Cleared by the US Food and Drug Administration (FDA), UltraClear operates by vaporising the skin's damaged outer layers and heating the underlying layers with controlled thermal energy, promoting the growth of new cells and boosting elastin and collagen production.

According to Acclaro Medical, the laser's cold beams aid in the removal of damaged epidermal cells, reducing side effects and pain.

Its beam quality facilitates consistent resurfacing outcomes, akin to an advanced form of exfoliation.

Alongside UltraClear, the company’s AuraLux laser utilises the exclusive Cool Pulse technology.

This expansion of the product line aims to enhance accessibility for providers and their patients.

Acclaro Medical co-founder and president Shlomo Assa said: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-ageing solutions for healthier and younger-looking skin.

“It greatly enables us to accelerate product development, expand our team, and reach more customers globally."

In 2022, Acclaro Corporation introduced the UltraClear laser technology system in the US.